<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310894</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN1001 PCM301</org_study_id>
    <nct_id>NCT01310894</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.</brief_title>
  <acronym>PCM301</acronym>
  <official_title>A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steba Biotech S.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steba Biotech S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are:

        -  to assess the impact of TOOKAD® Soluble-Vascular Targeted Photodynamic Therapy (VTP) on
           the rate of absence of definite cancer using patients on active surveillance as a
           comparison (co-primary objective A) and

        -  to determine the difference in rate of treatment failure associated with observed
           progression of disease from low risk prostate cancer to moderate or higher risk prostate
           cancer in men who undergo TOOKAD® Soluble-VTP compared to men on active surveillance
           (co-primary objective B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicentre, open label, randomised controlled study in subjects diagnosed
      with low risk prostate cancer on TransRectal Ultrasound (TRUS) guided biopsy.

      Subjects will be randomised to either Active Surveillance or TOOKAD® Soluble VTP. Subjects
      will remain in the study for approximately 24 months following randomisation. A total of 400
      subjects will be entered into the study; 200 will receive Active Surveillance and 200 will
      receive TOOKAD® Soluble-VTP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary endpoint 'A': Rate of absence of definite cancer using patients on active surveillance as a comparison.</measure>
    <time_frame>Month 24</time_frame>
    <description>Histological changes are assessed using biopsies or any other pathology result obtained during the study planned or not.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary endpoint 'B': Difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer.</measure>
    <time_frame>Over 24 months follow-up.</time_frame>
    <description>Moderate or higher risk is defined as the observation of:
More than 3 cores positive for cancer when considering all histological examination available during follow-up of study;
or any Gleason primary or secondary pattern 4 or more;
or at least one cancer core length greater than 5 mm;
or PSA&gt;10ng/mL ( in 3 consecutive measures);
or any T3 prostate cancer,
or metastasis;
or prostate cancer related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of additional prostate cancer radical therapy</measure>
    <time_frame>Over 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of cores positive for cancer</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of incontinence, erectile dysfunction, urinary symptoms</measure>
    <time_frame>Randomisation visit, Day 7 after VTP , Month 3, Month 6, Month 9, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of adverse events</measure>
    <time_frame>Screening-Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death</measure>
    <time_frame>Screening-Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall quality of life will be recorded for potential utility and descriptive studies.</measure>
    <time_frame>Randomisation visit; Month 12; Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">413</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TOOKAD® Soluble</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Active surveillance is one of the management strategy in men who have low-risk prostate cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOOKAD® Soluble</intervention_name>
    <description>TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance</description>
    <arm_group_label>TOOKAD® Soluble</arm_group_label>
    <other_name>WST11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible for inclusion in the study if all of the following criteria are
        met:

          1. Low risk prostate cancer diagnosed using one transrectal ultrasound guided biopsy
             (TRUS)using from 10 to 24 cores performed less than 12 months prior to enrolment, and
             showing the following:

               -  Gleason 3 + 3 prostate adenocarcinoma as a maximum,

               -  Two (2) to three (3) cores positive for cancer

               -  A maximum cancer core length of 5 mm in any core.

          2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease
             permitted)

          3. Serum prostate specific antigen (PSA) of 10 ng/mL or less

          4. Prostate volume equal or greater than 25 cc and less than 70 cc.

          5. Male subjects aged 18 years or older.

        Exclusion Criteria:

        Subjects will not be eligible for the study if meeting any of the following criteria:

          1. Unwillingness to accept randomisation to either of the two arms of the study

          2. Any prior or current treatment for prostate cancer, including surgery, radiation
             therapy (external or brachytherapy) or chemotherapy.

          3. Any surgical intervention for benign prostatic hypertrophy

          4. Life expectancy less than 10 years.

          5. Any condition or history of illness or surgery that may pose an additional risk to men
             undergoing the VTP procedure.

          6. Participation in another clinical study or recipient of an investigational product
             within 1 month of study entry.

          7. Subject unable to understand the patient's information document, to give consent or
             complete the study tasks.

          8. Subject in custody and or in residence in a nursing home or rehabilitation facility

          9. Contra-indication to Magnetic resonance Imaging (MRI) (e.g., pacemaker, history of
             allergic reaction to gadolinium), or factors excluding accurate reading of pelvic MRI
             (e.g., hip prosthesis)

         10. Any condition or history of illness or surgery that may pose an additional risk to men
             undergoing the TOOKAD® Soluble VTP procedure.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Emberton, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College of London Hospital , United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Urology-University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology-Tampere University Hospital-</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Médipole</name>
      <address>
        <city>Cabestany</city>
        <zip>66330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Sévigné</name>
      <address>
        <city>Cesson Sévigné</city>
        <zip>35512</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique d'Urologie et de Transplantation Rénale CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ambroise Paré</name>
      <address>
        <city>Neuilly sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris (IMM)</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris (IMM)</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Bleuets</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35 033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Urologique Nantes</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Krankenahaus GmbH</name>
      <address>
        <city>Bergisch Gladbach</city>
        <zip>51465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATURO-Gemeinschaftspraxis für Urologie und Andrologie</name>
      <address>
        <city>Berlin-Wilmersdorf</city>
        <zip>D-14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Emmendingen</city>
        <zip>79132</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinzenz Krankenhaus - Department of Urology</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München</name>
      <address>
        <city>Munich</city>
        <zip>D - 81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie 24</name>
      <address>
        <city>Nuremberg</city>
        <zip>90491</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Urologia Lucca - c/o Azienda USL 2 - Ospedale Campo di Marte</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Chirurgia Urologica Mininvasiva</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Urologica di Savona, Ospedale San Paolo di Savona</name>
      <address>
        <city>Savona</city>
        <zip>17100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polikliniek Urologie-Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellbitge-Servico de Urologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacio Puigvert-Department of Urology</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology-Hospital Clinic, University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre - Departmento de Urologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Del Rocio-Department Urology</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Urology-University Hospital-</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anna-Seiler-Haus Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital (KCH)</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford John Radcliffe Hospital Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>April 17, 2016</last_update_submitted>
  <last_update_submitted_qc>April 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Disease</keyword>
  <keyword>Genital Neoplasm,male</keyword>
  <keyword>Urogenital neoplasm</keyword>
  <keyword>Genital disease,male</keyword>
  <keyword>Male urogenital disease</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by site</keyword>
  <keyword>Prostatic neoplasm</keyword>
  <keyword>Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data are available in case report form for each patient</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

